Leith Wheeler Investment Counsel Ltd. adds Becton Dickinson and Co (BDX) to its portfolio

Becton Dickinson and Co (BDX) : Leith Wheeler Investment Counsel Ltd. added new position in Becton Dickinson and Co during the most recent quarter end. The investment management firm now holds 1,822 shares of Becton Dickinson and Co which is valued at $320,016 , the company said in a statement filed on Jul 6, 2016 with the SEC.Becton Dickinson and Co makes up approximately 0.28% of Leith Wheeler Investment Counsel Ltd.’s portfolio.

Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa reduced its stake in BDX by selling 31,923 shares or 19.4% in the most recent quarter. The Hedge Fund company now holds 132,612 shares of BDX which is valued at $23,291,972. Becton Dickinson and Co makes up approx 0.10% of Bnp Paribas Arbitrage Sa’s portfolio. Pensionfund Dsm Netherlands sold out all of its stake in BDX during the most recent quarter. The investment firm sold 25,400 shares of BDX which is valued $4,348,734.Stock Yards Bank Trust Co reduced its stake in BDX by selling 2,228 shares or 47.16% in the most recent quarter. The Hedge Fund company now holds 2,496 shares of BDX which is valued at $427,340. Becton Dickinson and Co makes up approx 0.06% of Stock Yards Bank Trust Co’s portfolio.Cacti Asset Management reduced its stake in BDX by selling 400 shares or 0.2% in the most recent quarter. The Hedge Fund company now holds 201,788 shares of BDX which is valued at $34,231,316. Becton Dickinson and Co makes up approx 3.71% of Cacti Asset Management’s portfolio.

Becton Dickinson and Co opened for trading at $175.97 and hit $177.01 on the upside on Monday, eventually ending the session at $176.35, with a gain of 0.40% or 0.71 points. The heightened volatility saw the trading volume jump to 7,17,600 shares. Company has a market cap of $37,422 M.

On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.